The Drug Discovery Services Company Evaluation Report 2025, published by MarketsandMarkets 360 Quadrants, analyzes the global drug discovery services market, evaluating over 150 companies and identifying the Top 25 leaders. The report highlights key players such as LabCorp, Evotec, and Selvita, emphasizing their roles in providing services like hit identification, medicinal chemistry, and hit-to-lead optimization. Market growth is driven by rising R&D investments, an expanding drug development pipeline, increased outsourcing due to high in-house development costs, and advancements in technologies such as AI, CRISPR, and organ-on-a-chip. The report also covers market dynamics, competitive strategies, financial metrics, and regional footprints of major companies, including Thermo Fisher Scientific, Charles River Laboratories, Wuxi Apptec, and others.

HTF Market Intelligence has released a comprehensive 143-page study on the global genetic engineering market, projecting it will grow from $10 billion in 2025 to $28 billion by 2032 at a compound annual growth rate (CAGR) of 14.2%. The market is segmented by type—including gene therapy, CRISPR gene editing, genetically modified crops, and synthetic biology—and by application such as medicine, agriculture, and industrial biotech. Key players include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Sangamo Therapeutics, and others. North America is the dominant region, while Asia-Pacific is the fastest-growing. Market drivers include advances in genome editing, demand for sustainable agriculture, and evolving regulatory frameworks. Challenges include ethical concerns, high costs, intellectual property disputes, and environmental risks. The report includes detailed analysis of market segments, competitive landscape, five forces, and PESTLE factors across global regions.

The Computer-Aided Drug Discovery (CADD) market was valued at USD 6.5 billion in 2024 and is projected to reach USD 13.44 billion by 2033, growing at a CAGR of 8.4% from 2025 to 2033. Pharmaceutical and biotech firms are increasingly adopting computational tools such as molecular modeling, artificial intelligence, and big-data analytics to accelerate drug discovery, reduce costs, and improve candidate identification. Key trends include AI/ML integration, cloud-based platforms, and personalized medicine. Major players include Dassault Systèmes, PerkinElmer, Schrödinger, Certara, Exscientia, Insilico Medicine, and OpenEye. The market is segmented by drug type, technology, therapeutic area, and end user. A competitive landscape analysis covers market share, revenue, product portfolio, and growth factors, with regional outlooks across North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Evotec AG has released its first-half 2025 financial results, reporting a 5% decline in group revenues to €371.2 million due to weak demand in the Discovery & Preclinical Development segment. The Just – Evotec Biologics segment outperformed with a 16% revenue increase. The company received significant payments from collaborations with Bristol Myers Squibb and a grant from The Gates Foundation for tuberculosis treatment development. Evotec has announced a potential sale of its Just – Evotec Biologics EU segment to Sandoz AG, expected to close in the fourth quarter, which may shift its operational focus. Despite some positive developments, the company faces ongoing financial challenges, including profitability and cash flow issues, leading to a 'Sell' rating and a $3.00 price target on its stock (EVO), with analyst sentiment being neutral.

Evotec SE has announced its first-half 2025 financial results, showing progress in executing its strategy for sustainable and profitable growth. The company reports a 5.0% decrease in group revenues to €371.2 million, driven by soft demand in its D&P&D segment, which declined 11.0% to €269.0 million. Just – Evotec Biologics, a key growth driver, saw a 16% revenue increase to €102.2 million, with strong performance from non-Sandoz and non-DoD customers. Adjusted Group EBITDA was €(1.9) million, in line with expectations due to strong cost control. Evotec also announced a potential sale of Just – Evotec Biologics' EU operations, including its Toulouse biologics manufacturing site, for around US$300 million in cash plus future technology-related payments. The company reported significant progress in collaborations with Bristol Myers Squibb (BMS), including a US$75 million performance-based and program-based payment and a US$20 million research payment. Evotec received a grant from The Gates Foundation to support tuberculosis treatment development and joined the NURTuRE-AKI consortium to expand its Molecular Patient Database. The company welcomed the FDA's roadmap to reduce animal testing, aligning with its long-term commitment to New Approach Methodologies (NAMs) and the 3-Rs principles. Evotec expects full-year group revenues between €760 million and €800 million, R&D spending between €40 million and €50 million, and adjusted EBITDA between €30 million and €50 million.